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Abstract
Objective. To investigate the patterns of myocardial involvement in the presence of self-limiting
and sustained systemic inflammation, using MRI.
Methods. Ninety-four subjects, with a clinical diagnosis of myocarditis (n=36), RA (n=24) and apparently
healthy subjects (n=34, control group), underwent standardized cardiac MRI protocol for the assessment
of global and regional morphology and systolic function using balanced steady-state free precession
sequences, T2-weighted images and late gadolinium enhancement (LGE) studies.
Results. The three groups were well matched for age, gender and cardiovascular risk factors. The RA
group showed markedly increased end-diastolic volumes and reduced ejection fraction (P<0.05). Antero/
inferolateral wall thickness was greater in the myocarditis group and reduced in RA, associated with
reduced radial and longitudinal thickening (P<0.01), and markedly raised T2-oedema ratio and global
LGE scores (P<0.05).
Conclusions. Our results may signify the phenotypic features of myocardial plasticity and deformation
in response to self-limiting and sustained inflammatory injury.
Key words: Cardiovascular, Systemic inflammation, Rheumatoid arthritis, Biomarkers, Magnetic
resonance imaging.
Introduction
Cardiovascular (CV) disease is a major cause of morbidity
and mortality in patients with systemic inflammatory
conditions, including RA, SLE and also chronic infections
with associated persistent inflammatory responses [1–6].
Available evidence suggests that these conditions are
associated with vascular dysfunction, as a consequence
of the inflammatory state and that this is linked to
increased CV risk [7–11]. Inflammatory involvement of
the myocardium in the presence of systemic inflam-
mation remains less well recognized [12]. While studies
in viral myocarditides indicate the presence of inflamma-
tory features, discernable by means of contemporary ima-
ging [13–16], it is unclear whether these changes evolve in
the presence of sustained systemic inflammation.
Cardiac MRI is emerging as a sensitive tool in the
evaluation of the structure and function of the heart, in
a variety of conditions, such as tumours, complex
congenital malformations, myocarditis, cardiomyopathy
and myocardial ischaemia [17]. In this study, we investi-
gate the patterns of myocardial response in the presence
of self-limiting myocardial inflammation, in the context
of myocarditis and sustained systemic inflammation
in patients with RA, by means of multiparametric
cardiac MRI.
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The study population consisted of adult subjects
(aged>16 years) drawn from the following participating
centres in this study: the Rheumatology Departments of
Hammersmith, Charing Cross and Northwick Park
Hospitals in the UK and the Cardiology Department, The
German Heart Institute, Berlin, Germany. The study was
reviewed and approved by the respective institutional
ethics committees (Charite ´ University School of
Medicine and Charing Cross and Queen Charlotte
National Research Ethics Committee). Informed written
consent was obtained from all participants in the study
according to the Declaration of Helsinki.
Group 1—patients with clinical criteria for myocarditis.
Diagnosis of myocarditis was based on the presence of
cardiac symptoms in the context of flu-like illness (chest
pain, shortness of breath and palpitations), evidence of
myocardial involvement (ECG abnormalities and elevated
cardiac enzymes—creatine kinase, troponin I or T) and
raised inflammatory biomarkers, e.g. CRP [14, 15].
Patients were recruited within the first 3 months of the
original presentation.
Group 2—patients with chronic RA and evidence of sus-
tained inflammatory response. Chronic, active RA was
defined by classification criteria for positive, poor-
prognosis disease of>10 years’ duration, positive RF,
positive for anti-cyclic citrullinated peptide (anti-CCP)
antibodies, persistently raised disease activity score
(DAS-28>7) and inflammatory biomarkers (CRP), meeting
the British Society for Rheumatology criteria for highly
active RA [18], and refractory to conventional DMARDs
and steroids, waiting to commence biologic therapies.
None of the patients was receiving biologic therapies at
the time of imaging.
Group 3—control group. Control groups consisted of
age-, gender-, BMI-, body surface area (BSA)-matched
apparently healthy subjects, recruited through advertise-
ment, with no evidence of systemic inflammatory
response, such as raised CRP or permanent anti-
inflammatory medication (aspirin, NSAIDs, corticoster-
oids, anti-histamines, etc.).
In addition, criteria of exclusion for all subjects were
previously known coronary artery disease, myocardial
infarction, heart failure, evidence of chronic myocarditis
(>3 months) and known contraindications to MRI. The
presence or absence of anti-hypertensive or cholesterol-
lowering medications was not used as a selection
criterion.
Clinical data
Standard clinical ‘meta-data’ were recorded for all sub-
jects, including demographics (age, gender, duration of
illness, smoking, diabetes, cholesterol level, etc.). All sub-
jects underwent a routine blood test for clinical
haematology and biochemistry, 12-lead ECG and blood
pressure (BP) measurement.
Multiparametric MRI
All participants underwent a standardized cardiac MRI
protocol (1.5T MRI Achieva; Philips Medical Systems,
The Netherlands) with subjects in supine position and a
five element-phased array cardiac coil, as previously
described [19, 20]. All subjects were in sinus rhythm to
allow accurate triggering and good quality image acquisi-
tion. Preparation scans included breath-held general
survey and two rapid heart axis survey scans [pseudo-
right, anterior oblique- and pseudo-four chamber (CH)
views].
Investigation into cardiac volumes and output.
Volumetric cavity assessment was obtained by whole-
heart coverage of gapless short-axis (SAX) slices using
a balanced steady-state free precession (bSSFP)
sequence [echo time (TE)/repetition time (TR)/flip angle
1.7 /3.4 /60 , spatial resolution 1.8 1.8 8mm and 50
heart phases] with typical 10–14 heartbeats used for
image acquisition. Investigation into myocardial plasticity
and deformation was assessed by two-, three- and four-
chamber and SAX slices with a bSSFP (as above). Max-
imal and regional left ventricular wall thickness (LVWT)
were obtained in three SAX slices (basal, equatorial and
apical) in a 16-segment analysis model. Investigation into
LV tissue is characterized by dual-inversion recovery T2-
weighted spin-echo sequences performed in three analo-
gous SAX slice acquisitions; matrix size 384 384; slice
thickness 8mm; echo time=90ms; relaxation time
1500ms; and TR (beats) =2. Calculation of oedema
ratio (ER) was performed as previously described [13–
15]. Late gadolinium enhancement (LGE) was performed
using a diastolic-triggered inversion-prepared 3D spoiled
gradient echo sequence (TE/TR/flip=1.7ms, 3.5ms, 15
dg; spatial resolution 1.8 2 10mm reconstructed to
1.8 1.8 5mm, with patient-adapted pre-pulse delay)
for 10min following contrast injection (gadolinium-diethy-
lenetriamine penta-acetic acid, dose of 0.2mmol/kg body
weight).
Dataanalysis
Data analysis was performed using dedicated cardiac
software (ViewForum, Version 5.1; Philips Medical
Systems, The Netherlands) and Excel-based post-
processing macros, developed in-house. Myocardial
deformation was assessed by the calculation of radial
and longitudinal strains, as a percentage of change of
thickness of radial segments and lengths of longitudinal
walls [21, 22]. Quantitative analysis of LGE for the pres-
ence of global (total LV volume) and regional (correspond-
ing three SAX slices for segmental analysis) enhancement
(percentage of enhanced volume=enhanced volume/
non-enhanced volume) was done with the manual selec-
tion of normal area, appearing as maximally suppressed
myocardium anywhere within the 3D volume. To avoid
confounding for artefacts, a conservative threshold for
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normal area [13–15].
Calculation of BMI, BSA and LV wall stress was
performed using validated formulas [23–26]. Statistical
analysis was performed using SPSS software (version
15.0; SPSS, Chicago, IL, USA). For comparison of two
and more than two normally distributed variables,
Student’s t-test, one-way analysis of variance (ANOVA,
with Bonferroni’s post-hoc test) and the chi-square test
were employed as appropriate. Correlations were
assessed using Pearson’s correlation coefficient for nor-
mally distributed variables and Spearman’s correlation
coefficient for non-parametric data. Data are expressed
as mean (1 S.D.); P<0.05 was considered statistically
significant.
Results
Clinical characteristics
Table 1 provides the characteristics of the study popula-
tion. Participants were well matched for BSA/BMI, age
and gender, with predominance of females in all groups.
The groups were also well matched for traditional CV risk
factors with no significant difference in BP, smoking, total
cholesterol levels among groups; none of the subjects
was diagnosed with either impaired glucose tolerance or
overt diabetes. Table 2 summarizes the medications taken
by the study groups, indicating the greater share of CV
medication in the RA group.
In the myocarditis group, the average duration between
the onset of cardiac symptoms and MRI was 44.9 (19.8)
days. The majority of patients presented with acute onset
of chest pain (78%), shortness of breath (28%) and palpi-
tations (30%). Tiredness was noted in three patients
as the presenting symptom. ECG-wise, 28 patients
showed significant changes in ST-segment (depression,
elevation, negative T waves in52 leads). In addition,
eight patients had a documented supraventricular
tachyarrhythmia and five paroxysmal atrial fibrillation.
Half of the patients showed persistently raised inflamma-
tory biomarkers (Table 1). In terms of cardiac markers, 20
patients had raised creatine kinase (CK) levels
[198.3 (134.26) ng/ml] with positive CK-MB fraction
[42.3 (26.3) ng/ml] and 13 had a detectable troponin rise
[2.5 (0.22) ng/ml] at the time of presentation. In addition,
12 patients showed concomitant presence of small peri-
cardial effusion (Fig. 1A). On clinical examination, none of
the subjects exhibited signs of heart failure. None of these
subjects took any cardiotoxic medication or an excessive
amount of alcohol before this episode.
In the RA group, patients had had condition for an aver-
age of 12.3 (5.4) years, had detectable titres of RF and
anti-CCP antibodies and evidence of persistently raised
inflammatory markers, such as CRP. All patients had a
routine measurement of CK and troponin I at enrolment,
none of them reaching the positive threshold as per local
hospital reference (>0.032ng/ml). There were no signifi-
cant ECG changes either in duration of intervals or signif-
icant ST changes. These patients took a variety of
DMARDs and NSAIDs (Table 2). None of the patients
took gold preparations.
Global cardiac functional performance
While both inflammatory groups exhibited reduced
ejection fraction (EF), the RA group showed markedly
increased end-diastolic volume (EDV) and to a lesser
TABLE 1 Characteristics of the study population
Normal,
n=34
Myocarditis,
n=36
RA,
n=24 P-value
Age, mean (S.D.), years 42.2 (12.1) 40.6 (14.9) 46.1 (9.1) 0.12
Gender (males), n (%) 11 (32) 12 (33) 8 (33.3) 0.85
BP systolic, mean (S.D.), mmHg 121.1 (10.7) 122.5 (13.3) 128 (15.1) 0.27
BP diastolic, mean (S.D.), mmHg 78.7 (7.8) 79.1 (9.7) 84.5 (9.9) 0.21
BMI, mean (S.D.), kg/m
2 24.5 (3) 25.2 (4.3) 25.6 (5) 0.97
BSA, mean (S.D.), m
2 1.7 (0.3) 1.7 (0.3) 1.7 (0.3) 0.94
Total cholesterol, mean (S.D.), mmol/l 4.6 (2.4) 4.7 (1.2) 5.2 (3.1) 0.35
Smoking, n (%) 2 (6) 3 (8) 1 (4) 0.54
CRP, mean (S.D.), mg/l 4.7 (3.1) 32.3 (6.3) 48.3 (26.5) F=3.9, P=0.01*
,y
*Normal vs myocarditis. yNormal vs RA. P<0.05 is considered significant.
TABLE 2 Medication of the study population
Medication
Normal
(n=34),
n (%)
Myocarditis
(n=36),
n (%)
RA (n=24),
n (%)
CV
b-Blockers 2 (6) 0 (0) 3 (12.5)
Amlodipine 6 (17.6) 5 (13.9) 8 (33.3)
RAS inhibitors 8 (23.5) 7 (19.4) 9 (37.5)
Statins 15 (44.1) 14 (38.8) 10 (41.7)
Anti-rheumatic
Prednisolone – – 22 (91.7)
SSZ – – 24 (100)
MTX – – 22 (91.7)
HCQ – – 23 (95.8)
NSAIDs – 11 (30.6) 21 (87.5)
RAS: renin–angiotensin system.
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Valentina O. Puntmann et al.Fig. 1 Representative images of a patient with myocarditis (A) and RA (B). In (A), cine frames at end-diastole (ED)
and end-systole (ES) in SAX indicate increased wall thickness (1-ED and 1-ES), reduced contractility and the presence
of a small pericardial effusion (yellow arrow). In (B), there is cavity enlargement, wall thinning and reduced thickening
(2-ED and 2-ES). T2-weighted (T2W) and LGE images show evenly distributed signal intensity and absence of focal
fibrosis in both cases.
A
B
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normal group. Difficulty in functional assessment in RA
patients due to the problems in mobility notwithstanding,
none of the patients exhibited symptoms or signs of overt
heart failure at rest. Given the lower EF finding in the RA
group, some patients may have been in the New York
Heart Association (NYHA) I/II class (Table 3).
Regional LV plasticity and deformation
Patients with myocarditis and RA displayed changes in
LVWT, particularly in the lateral segments, in opposing
directions: antero/inferolateral wall thickness was greater
in the myocarditis group and reduced in RA, in all three
SAX levels. These findings were associated with reduced
radial and longitudinal systolic strains (P<0.01; Table 4)
and little change in radial strains in either patient group.
Tissue characterization—T2-ER and LGE
Although regional oedema was not visually detectable on
T2-weighted MRI images, the global-T2-ER was raised in
both inflammatory conditions [global ER: normal 2.5 (3.9);
myocarditis 4.9 (3.2); RA 3.7 (3.2); F=3.1; P=0.05]
(Fig. 1A and B). LGE revealed no evidence of myocardial
scar suggestive of previous infarct in epicardial coronary
territory in any of the three groups. Global LGE score was
raised mildly in only the myocarditis group [6.8 (6.2)], and
significantly in the RA group [10.5 (5.2)] when compared
with the control level [2.3 (3.9); F=5.3; P=0.01].
Analysis of the relationship between imaging mea-
surements and inflammatory biomarkers showed, in the
myocarditis group, a trend of association between CRP
and T2-ER (r=0.8; P=0.07) and a significant correlation
between CRP and anterolateral longitudinal strain
TABLE 4 Radial and longitudinal regional systolic deformation
Systolic strain
Normal (n=34),
mean (S.D.)
Myocarditis (n=36),
mean (S.D.)
RA (n=24),
mean (S.D.) P-value
Radial
Total 21 (9.2) 20.5 (8.8) 22.2 (8.4) 0.38
Apical 22.7 (11.5) 26.3 (14.3) 26.8 (12.7) 0.13
Equatorial 20.2 (12.3) 20.9 (10.3) 24.4 (11.5) 0.5
Basal 18.3 (6.8) 14.2 (7.2) 16.8 (4.6) 0.7
Longitudinal
Total 19 (3.4) 18.3 (3.5) 16.1 (7.8) F=3.1, P=0.05*
,y
Anterior 18 (5) 18.4 (6.2) 21.4 (6.1) 0.52
Anteroseptal 18.7 (5) 19.4 (6.7) 19.3 (4.3) 0.22
Inferoseptal 22.2 (6.6) 19.6 (5) 17.5 (4.6) F=3.1, 0.05*
Inferior 20.2 (5.9) 17.6 (7.2) 17.3 (5.6) F=3.1, 0.05*
,z
Inferolateral 20.2 (5.9) 17.2 (7.5) 16.2 (6.8) F=3.4, 0.02*
,z
Anterolateral 20.7 (13.7) 17.6 (7.2) 16.1 (5.9) F=3.2, 0.04y,z
RV free wall 24.2 (6.8) 26.2 (7) 27.6 (8.3) 0.57
*Normal vs RA. yMyocarditis vs RA. zNormal vs myocarditis; P<0.05 is considered significant.
TABLE 3 Measures of LV cardiac function and morphology
Normal (n=34),
mean (S.D.)
Myocarditis (n=36),
mean (S.D.)
RA (n=24),
mean (S.D.) P-value
LV mass, g 87.7 (31.6) 88.1 (27.2) 80.5 (21.5) 0.48
LV mass index, g/m
2 59.8 (17.2) 57.7 (18) 64.1 (23.5) 0.85
Heart rate, b.p.m. 75.3 (9.1) 67.6 (12.4) 72.1 (6.0) 0.35
LV wall stress, dynes/cm
2 146.0 (31.3) 146.1 (31.1) 146.6 (34.7) 0.66
Interventricular septum, mm 9.1 (2.1) 9.4 (2.5) 8.2 (2.1) 0.62
Posterior wall thickness, mm 8.9 (1.8) 7.9 (1.9) 7.5 (2) 0.17
EF, n (%) 62.2 (6.5) 53.4 (6.3) 45.8 (8.8) F=3.1, 0.05*
EDV, ml 123.1 (15.3) 133.5 (24.8) 150.2 (31.8) F=3.1, 0.05*
ESV, ml 65.6 (25.7) 70.4 (22.3) 76.2 (26.5) 0.1
Stroke volume, ml 58.3 (13.3) 63.1 (11.7) 59.2 (15.1) F=2.1, 0.09
Cardiac output, l/min 4.8 (1.3) 4.3 (1.1) 4.8 (1.1) 0.12
Left atrium, cm
2 23.2 (5.8) 24.9 (5.3) 26.2 (5.2) F=3.1, 0.05*
Right atrium, cm
2 22 (2.9) 22.8 (4.6) 23.2 (4.8) 0.66
*Normal vs RA. P<0.05 is considered significant. LV: left ventricle.
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ciations with inflammatory markers were noted: (i) CRP
levels inversely correlated with SV (r= 0.6; P=0.02)
and cardiac output (r= 0.6; P=0.007); (ii) RF titres cor-
related with global T2-ER score (r=0.7; P=0.04); and (iii)
anti-CCP titres correlated with EF (r= 0.7; P=0.02) and
global T2-ER score (r=0.6; P=0.05). Moreover, global
LGE score displayed a significant association with EDV
(r= 0.5; P=0.01). There was no association between
inflammatory biomarkers and CV risk factors (BP, choles-
terol level or smoking status), even when controlling for
the presence of CV medication.
Discussion
We demonstrate, using multiparametric cardiac MRI,
the presence of a myocardial inflammatory response
occurring in the context of self-limiting and sustained
inflammatory injury. Both conditions reveal global systolic
impairment, in line with globally raised tissue characteris-
tic scores. While myocardial response to self-limiting
injury is by wall thickening, the presence of incessant
inflammatory harm is characterized by thinned myocar-
dium and enlarged cavities. Of note, in both conditions,
the lateral segments appear to be central to this response,
displaying the peak of inflammatory change in plasticity
and deformation. To the best of our knowledge, this study
is the first to examine myocardial function and structure in
the presence of sustained systemic inflammation in RA,
and to compare and contrast it with a recognized pheno-
typic model of myocardial inflammation and with healthy
control subjects.
Myocarditis represents an inflammation of myocardial
tissue, and is likely to be under-diagnosed. In most
patients, it develops in the context of infectious disease
(via direct viral infection or post-viral immune-mediated
reaction), however, myocardial injury via environmental
exposure, such as drug- or alcohol-related toxicity, has
also been described as a trigger of myocardial inflamma-
tion [27, 28]. Pathogenesis includes myocyte injury, local
and systemic cytokine-mediated immune responses
and cell activation with subsequent cellular infiltration,
oedema and necrosis. Fibrotic scarring is also a
common feature [28]. Various characteristics observed
on imaging have been described, including ventricular
failure, wall thickening, regional oedema and fibrosis.
Of note, no single clinical or imaging finding confirms
the diagnosis of myocarditis with pathognomonic
certainty [14, 27].
Our myocarditic cohort exhibits features consistent with
these previous observations, including reduced systolic
function, increased wall thickness and impaired longitudi-
nal strains, particularly affecting the lateral segments.
Reduced systolic performance is likely due to myocardial
oedema, which is diffusely spread in the sub-acute phase.
Previous findings [29] identified a greater likelihood of
lateral wall involvement, indicating the potential presence
of a feeble myocardial region, sensitive to inflammatory
injury. Our findings are further supported by the
link between CRP and regional longitudinal strain.
Previously, no correlation was found between inflamma-
tory biomarkers and tissue characterization measures;
this finding is reproduced in our study [15]. Absence of a
firm association between CRP and T2-ER score may
emphasize the intricacy of subtle tissue changes and
likely a need for a greater sample size.
The contemporary view holds CV disease as a dynamic
and progressive pathology arising from the combination of
endothelial dysfunction, oxidative stress and insulin resis-
tance, with inflammation acting as the common denomi-
nator in these processes. Indeed, patients with RA have a
two to five times increased risk of developing severe and
premature CV disease with shorter life expectancy by 5–
10 years, even when matched for traditional CV risk fac-
tors [1–8]. The link between increased CV risk and inflam-
mation is supported by a host of vascular evidence
(endothelial dysfunction, reduced arterial elasticity and
compressibility and increased atherosclerotic burden)
[9–11].
Raised levels of inflammatory mediators, such as TNF-
a, IL-1, -6 and increased activity of proteolytic enzymes
(MMPs), have been implicated in inflammatory tissue
injury, such as joint destruction and destabilization of vul-
nerable plaques [30–33]. It is, therefore, conceivable that
the association of elevated inflammatory cytokine levels
may also lead to concomitant myocardial tissue injury.
Previous studies investigated the role of a pro-
inflammatory cytokine profile in the development of LV
dysfunction and cardiomyopathy in an animal model and
humans subjects [34–37]. Persistently raised and patho-
physiologically relevant circulating concentrations of TNF-
a lead to deleterious changes in LV structure and function,
with time-dependent depression in LV function, cardiac
myocyte shortening and LV dilation. These mechanisms
appear to involve simultaneous increase in fibrillar content
and activation of collagenolytic enzymes, MMPs [38].
Progressive degradation of fibrillar collagen facilitates
mural realignment of myofibrillar bundles and leads to
increased LV wall thinning and LV dilation [39].
The findings in our RA cohort correspond well to these
postulations and provide an important insight into myo-
cardial responses in the presence of sustained systemic
inflammation. Ongoing inflammatory injury and persis-
tence of tissue oedema in RA myocardium is reflected in
increased T2-ER. Wall thinning and cavity dilation with
reduced global systolic performance reveal globally
affected myocardial tissue. Globally raised LGE score
may correspond to diffuse myocardial fibrosis [16, 37].
Moreover, despite the absence of overt symptoms, the
greater share of CV medication in the RA group reflects
the degree of disease progression, which may, in line with
the finding of lower EF, further suggest that some of these
patients may have been in NYHA I/II class. Significant
associations between inflammatory markers and func-
tional imaging measurements thus support the hypothesis
that these changes reflect sustained inflammatory myo-
cardial injury and potentially signify the phenotypic fea-
tures of myocardial plasticity in response to sustained
inflammatory injury.
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Addressing CV risk in the RA population remains an
important priority. A distinctive myocardial inflammatory
phenotype, discernable by means of non-invasive ima-
ging, may provide a bio-signature of the sequelae of sys-
temic inflammatory responses affecting the heart muscle.
The findings of this study may provide the basis for a
future randomized controlled clinical trial, addressing CV
endpoints, CV prevention strategies as well as proving
useful in assessments of any CV benefit/harm of existing
and emerging therapeutic intervention in this susceptible
population.
Limitations
Few limitations apply to our study. Assessment of regional
strain values in this study was performed by employing
the physiological principles and validated formulas pre-
viously described [21, 22]; however, measurements in
this study have been made on the cine images. The
choice of this approach over other described methodolo-
gies of assessment of deformation with MRI offers higher
temporal resolution, 16-segment analysis, fast post-
processing analysis and potential for use in routine clinical
application. Next, involvement of skeletal muscle in sys-
temic inflammation may limit the sensitivity of a signal
intensity analysis normalized to skeletal muscle [14, 16]
and should be taken into consideration in patients with
evidence of skeletal muscle inflammation. Lastly, this
study aimed to establish physiological relationships in
sub-acute and chronic inflammatory phenotypes, identify-
ing RA patients comparable with those encountered in the
more studied myocarditis population. Future studies are
needed to translate the present findings to the general
rheumatoid population.
Conclusions
Taken together, the present findings may signify the
phenotypic features of myocardial plasticity and
deformation in response to self-limiting and sustained
inflammatory injury.
Rheumatology key messages
. Self-limiting and sustained inflammatory injury may
have phenotypic features of myocardial plasticity
and deformation.
. A potential phenotypic myocardial signature may
have utility in CV prevention strategies in
susceptible populations.
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